Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
40433 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A42893 | 33179900 | Am Fam Physician | Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A42894 | 33179266 | Hepatology | MRI-Proton Density Fat Fraction Treatment Response Criteria in Nonalcoholic Steatohepatitis. | 2021 | Details |
| A42895 | 33176064 | Liver Int | The association of low-grade albuminuria with incident nonalcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycemic status. | 2020 | Details |
| A42896 | 33164861 | Metabolism | Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. | 2020 | Details |
| A42897 | 33163839 | Hepatol Commun | Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. | 2020 | Details |
| A42898 | 33163833 | Hepatol Commun | ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. | 2020 | Details |
| A42899 | 33163517 | Hepatobiliary Surg Nutr | The Mediterranean diet and nonalcoholic fatty liver disease in individuals at high cardiovascular risk. | 2020 | Details |
| A42900 | 33163514 | Hepatobiliary Surg Nutr | Is there a safe threshold for alcohol consumption in nonalcoholic fatty liver disease? | 2020 | Details |
| A42901 | 33160928 | PET Clin | Total-body PET Imaging: A New Frontier for the Assessment of Metabolic Disease and Obesity. | 2020 | Details |
| A42902 | 33159427 | Liver Int | Targeting pathobionts for the treatment of alcohol-associated liver disease. | 2020 | Details |
| A42903 | 33157317 | Clin Gastroenterol Hepatol | Epidemiologic Landscape of Nonalcoholic Fatty Liver Disease Is Changed During Lifetime by Menstrual and Reproductive Status and Sex Hormonal Factors. | 2020 | Details |
| A42904 | 33149083 | Curr Opin Lipidol | Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart. | 2020 | Details |
| A42905 | 33146683 | JAMA Cardiol | Genetic Inhibition of PCSK9 and Liver Function. | 2021 | Details |
| A42906 | 33145629 | J Med Ultrason (2001) | On the occasion of publication of the feature on diagnosis and assessment of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis using ultrasound elastography. | 2020 | Details |
| A42907 | 33142445 | Poult Sci | Maintaining intestinal structural integrity is a potential protective mechanism against inflammation in goose fatty liver. | 2020 | Details |
| A42908 | 33142057 | J Med Chem | A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor γ Binding Properties and Biological Activities. | 2020 | Details |
| A42909 | 33140925 | Minerva Med | Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease. | 2020 | Details |
| A42910 | 33130185 | J Hepatol | Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues". | 2020 | Details |
| A42911 | 33125345 | Aging (Albany NY) | MerTK, a risk factor for NASH fibrosis. | 2020 | Details |
| A42912 | 33123088 | Front Endocrinol (Lausanne) | The Impact of Adipose Tissue-Derived miRNAs in Metabolic Syndrome, Obesity, and Cancer. | 2020 | Details |
| A42913 | 33117357 | Front Immunol | Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. | 2020 | Details |
| A42914 | 33105983 | Aliment Pharmacol Ther | Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data. | 2020 | Details |
| A42915 | 33105979 | Aliment Pharmacol Ther | Letter: proving the benefit of exercise intervention in metabolic associated fatty liver disease-authors' reply. | 2020 | Details |
| A42916 | 33105976 | Aliment Pharmacol Ther | Letter: proving the benefit of exercise intervention in non-alcoholic fatty liver disease. | 2020 | Details |
| A42917 | 33096086 | J Hepatol | Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points. | 2020 | Details |
| A42918 | 33092756 | JACC Clin Electrophysiol | Risk Factor Modification for Atrial Fibrillation: An Ounce of Prevention. | 2020 | Details |
| A42919 | 33089797 | Hong Kong Med J | Non-alcoholic fatty liver disease in non-obese children. | 2020 | Details |
| A42920 | 33089485 | Dig Dis Sci | Arrested Development: Slow Progression of Fibrosis in Patients with NAFLD and IBD. | 2020 | Details |
| A42921 | 33088502 | Arch Public Health | Eating quickly is associated with a low aspartate aminotransferase to alanine aminotransferase ratio in middle-aged adults: a large-scale cross-sectional survey in Japan. | 2020 | Details |
| A42922 | 33088253 | EXCLI J | Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)? | 2020 | Details |
| A42923 | 33085985 | Aliment Pharmacol Ther | Letter: substantial under-diagnosis of NAFLD - more efforts are needed globally. | 2020 | Details |
| A42924 | 33083281 | Liver Cancer | The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017. | 2020 | Details |
| A42925 | 33077572 | Gut | NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought. | 2020 | Details |
| A42926 | 33077366 | Hepatobiliary Pancreat Dis Int | Serum non-high-density lipoprotein cholesterol level is increased in Chinese patients with nonalcoholic fatty liver disease. | 2020 | Details |
| A42927 | 33068450 | Liver Int | Pulmonary function is associated with fibrosis severity in patients with biopsy-proven nonalcoholic fatty liver disease. | 2021 | Details |
| A42928 | 33058739 | Am J Respir Crit Care Med | Blowing Away Fatty Liver: Mission Impossible? | 2021 | Details |
| A42929 | 33053354 | Cell Rep | Prostaglandin E2-EP4 Axis Promotes Lipolysis and Fibrosis in Adipose Tissue Leading to Ectopic Fat Deposition and Insulin Resistance. | 2020 | Details |
| A42930 | 33047634 | Expert Opin Drug Saf | Statins in liver cirrhosis in a developing country: benefits overweigh the risk? | 2020 | Details |
| A42931 | 33047337 | Hepatology | Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss. | 2021 | Details |
| A42932 | 33045621 | Redox Biol | Homocysteine promotes hepatic steatosis by activating the adipocyte lipolysis in a HIF1α-ERO1α-dependent oxidative stress manner. | 2020 | Details |
| A42933 | 33045592 | Environ Pollut | 4-Hexylphenol influences adipogenic differentiation and hepatic lipid accumulation in vitro. | 2020 | Details |
| A42934 | 33044023 | J Cell Physiol | Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment. | 2020 | Details |
| A42935 | 33041339 | Cell Mol Immunol | Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer. | 2020 | Details |
| A42936 | 33034103 | Liver Int | The association of low-grade albuminuria with incident nonalcoholic fatty liver disease and non-invasive markers of liver fibrosis. | 2021 | Details |
| A42937 | 33032848 | J Hepatol | NFATc4: New hub in NASH development. | 2020 | Details |
| A42938 | 33032512 | Curr Vasc Pharmacol | Editorial on Prevalence, Diagnosis and Treatment with 3 Different Statins of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? | 2021 | Details |
| A42939 | 33031804 | Cell Mol Gastroenterol Hepatol | Characterizing the Heterogeneity of Liver Cell Populations Under a NASH-Related Hepatotoxicant Using Single-Nuclei RNA Sequencing. | 2020 | Details |
| A42940 | 33024912 | Hepatol Commun | Health Care Resource Use and Cost Burden of Chronic Kidney Disease in Patients With Chronic Liver Disease: A Real-World Claims Analysis. | 2020 | Details |
| A42941 | 33023724 | Clin Investig Arterioscler | Control del riesgo cardiovascular, la enfermedad metabólica y la esteatosis hepática a través del empoderamiento de la salud: una propuesta de futuro. | 2021 | Details |
| A42942 | 33021827 | Annu Rev Cell Dev Biol | Protein Quality Control and Lipid Droplet Metabolism. | 2020 | Details |
| A42943 | 33012657 | Dig Liver Dis | NAFLD, MAFLD and DAFLD. | 2020 | Details |
| A42944 | 33012546 | J Hepatol | NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials. | 2020 | Details |
| A42945 | 33001002 | Curr Pharm Des | NAFLD in the 20's. From Epidemiology to Management (PART - II). | 2020 | Details |
| A42946 | 32994080 | J Hepatol | Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease. | 2020 | Details |
| A42947 | 32994079 | J Hepatol | FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD). | 2020 | Details |
| A42948 | 32991019 | Int J Clin Pract | Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection. | 2020 | Details |
| A42949 | 32988545 | Poult Sci | Research Note: Increase of bad bacteria and decrease of good bacteria in the gut of layers with vs. without hepatic steatosis. | 2020 | Details |
| A42950 | 32981752 | J Hepatol | Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)". | 2020 | Details |
| A42951 | 32980092 | Semin Ultrasound CT MR | Pearls and Pitfalls of Metabolic Liver Magnetic Resonance Imaging in the Pediatric Population. | 2020 | Details |
| A42952 | 32979160 | Dig Dis Sci | NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease. | 2020 | Details |
| A42953 | 32973038 | J Lipid Res | Characterization of essential domains in HSD17B13 for cellular localization and enzymatic activity. | 2020 | Details |
| A42954 | 32971587 | Clin Mol Hepatol | Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated "enemy"? | 2020 | Details |
| A42955 | 32971038 | Cell Mol Gastroenterol Hepatol | Vitamin A in Nonalcoholic Fatty Liver Disease: A Key Player in an Offside Position? | 2020 | Details |
| A42956 | 32970909 | Liver Int | Liver adenomatosis and NAFLD developed in the context of hereditary fructose intolerance. | 2020 | Details |
| A42958 | 32965684 | Hepatology | Letter to the Editor: Nonalcoholic Fatty Liver Disease-One Size May Not Fit All. | 2021 | Details |
| A42959 | 32958329 | J Hepatol | From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance. | 2020 | Details |
| A42960 | 32951911 | J Hepatol | Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease". | 2020 | Details |
| A42961 | 32951910 | J Hepatol | Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". | 2020 | Details |
| A42962 | 32944995 | J Gastroenterol Hepatol | Are low triglyceride levels the cause or an outcome of advanced liver fibrosis in elderly patients with nonalcoholic fatty liver disease? | 2020 | Details |
| A42963 | 32941668 | Liver Int | Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world. | 2020 | Details |
| A42964 | 32939550 | J Nutr | A Novel Combination of Fruits and Vegetables Prevents Diet-Induced Hepatic Steatosis and Metabolic Dysfunction in Mice. | 2020 | Details |
| A42965 | 32933781 | J Hepatol | Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate. | 2020 | Details |
| A42966 | 32933780 | J Hepatol | On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. | 2020 | Details |
| A42967 | 32932282 | Chin Med J (Engl) | Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. | 2020 | Details |
| A42968 | 32930521 | Liver Int | MAFLD vs NAFLD: Let the contest begin! | 2020 | Details |
| A42969 | 32930093 | Elife | SWELL1 regulates skeletal muscle cell size, intracellular signaling, adiposity and glucose metabolism. | 2020 | Details |
| A42970 | 32925302 | J Clin Gastroenterol | Lean and Nonobese NAFLD/NASH From a Hepatologist's Point of View. | 2021 | Details |
| A42971 | 32923835 | Hepatol Commun | Self-Organizing Human Induced Pluripotent Stem Cell Hepatocyte 3D Organoids Inform the Biology of the Pleiotropic TRIB1 Gene. | 2020 | Details |
| A42972 | 32923832 | Hepatol Commun | Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. | 2020 | Details |
| A42973 | 32922753 | Clin Liver Dis (Hoboken) | Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A42974 | 32922750 | Clin Liver Dis (Hoboken) | Nonalcoholic Fatty Liver Disease: Making the Diagnosis. | 2020 | Details |
| A42975 | 32914727 | Endocr Metab Immune Disord Drug Targets | Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine. | 2021 | Details |
| A42976 | 32906011 | Pathol Res Pract | Correlation between M30 immunochemistry and histological activity in steatohepatitis: One piece of a complex puzzle. | 2020 | Details |
| A42977 | 32902951 | ACS Nano | Biomolecular Ultrasound Imaging of Phagolysosomal Function. | 2020 | Details |
| A42978 | 32899741 | Life (Basel) | Fatty Liver, and Not Visceral Fat, Is More Associated with Liver Fibrosis and Diabetes in Non-Obese Japanese Individuals: A Cross-Sectional Study. | 2020 | Details |
| A42979 | 32896123 | ACS Sens | Early Multiplexed Detection of Cirrhosis using Giant Magnetoresistive Biosensors with Protein Biomarkers. | 2020 | Details |
| A42980 | 32895142 | Nan Fang Yi Ke Da Xue Xue Bao | [Gut microbiota-an important contributor to liver diseases]. | 2020 | Details |
| A42981 | 32894342 | Handb Exp Pharmacol | How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development. | 2021 | Details |
| A42982 | 32891071 | Liver Int | Non-alcoholic fatty liver disease (NAFLD) in Asia-More efforts are needed. | 2020 | Details |
| A42983 | 32890593 | J Hepatol | The times they are a-changin' (for NAFLD as well). | 2020 | Details |
| A42984 | 32889767 | Liver Int | Authors' response to 'Concordance of MAFLD and NAFLD diagnostic criteria in "real-world" data'. | 2020 | Details |
| A42985 | 32887953 | Nat Rev Gastroenterol Hepatol | Determining the reliability of liver biopsies in NASH clinical studies. | 2020 | Details |
| A42986 | 32887949 | Nat Rev Endocrinol | Role of fructose in NASH defined. | 2020 | Details |
| A42987 | 32886383 | Aliment Pharmacol Ther | Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD. | 2020 | Details |
| A42988 | 32886382 | Aliment Pharmacol Ther | Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD-Authors' reply. | 2020 | Details |
| A42989 | 32886356 | Aliment Pharmacol Ther | Letter: genetic associations of non-alcoholic fatty liver, malignancies and heart disease. | 2020 | Details |
| A42990 | 32882164 | Cell Metab | A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance. | 2020 | Details |
| A42991 | 32876833 | Eur Radiol | Intravoxel incoherent motion diffusion-weighted MRI for the characterization of inflammation in chronic liver disease. | 2020 | Details |
| A42992 | 32870294 | JAMA | Nonalcoholic Steatohepatitis-Reply. | 2020 | Details |
| A42993 | 32870291 | JAMA | Nonalcoholic Steatohepatitis. | 2020 | Details |